Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects .
Ayalasomayajula S, Langenickel TH, Chandra P, Wolfson ED, Albrecht D, Zhou W, Pal P, Rajman I, Sunkara G. Ayalasomayajula S, et al. Int J Clin Pharmacol Ther. 2016 Dec;54(12):1012-1018. doi: 10.5414/CP202604. Int J Clin Pharmacol Ther. 2016. PMID: 27719743 Clinical Trial.
However, systemic exposure (AUC(inf) and AUC(last)) of sacubitril was slightly decreased (by 16% with low-fat meal) and that of sacubitrilat was unchanged in the presence of food. For valsartan, the C(max) decreased by ~ 40% when LCZ696 was administered after low- a …
However, systemic exposure (AUC(inf) and AUC(last)) of sacubitril was slightly decreased (by 16% with low-fat meal) and that of sacubitri …
Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
Ayalasomayajula SP, Langenickel TH, Jordaan P, Zhou W, Chandra P, Albrecht D, Pal P, Rajman I, Sunkara G. Ayalasomayajula SP, et al. Eur J Clin Pharmacol. 2016 Sep;72(9):1065-73. doi: 10.1007/s00228-016-2072-7. Epub 2016 May 26. Eur J Clin Pharmacol. 2016. PMID: 27230850 Clinical Trial.
Following oral administration, LCZ696 provides systemic exposure to valsartan and sacubitril (a prodrug), and its metabolite sacubitrilat (the active neprilysin inhibitor, formerly named as LBQ657), which is eliminated primarily via renal route. ...CONCLUSION: Renal …
Following oral administration, LCZ696 provides systemic exposure to valsartan and sacubitril (a prodrug), and its metabolite sacub …
Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
Akahori M, Ayalasomayajula S, Langenickel T, Pal P, Zhou W, Sunkara G. Akahori M, et al. Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):407-416. doi: 10.1007/s13318-016-0354-1. Eur J Drug Metab Pharmacokinet. 2017. PMID: 27324506 Clinical Trial.
Plasma and urine samples from 40 subjects receiving LCZ696 were collected to assess pharmacokinetics of LCZ696 analytes (sacubitril, sacubitrilat, and valsartan). RESULTS: Following single oral dose administration of LCZ696, sacubitril and valsartan rapidly a …
Plasma and urine samples from 40 subjects receiving LCZ696 were collected to assess pharmacokinetics of LCZ696 analytes (sacubitril, sacu …